Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Compared with aspirin, apixaban lowered the risk of stroke or systemic embolism but increased the risk of major bleeding in patients with subclinical atrial fibrillation,
Compared with aspirin, apixaban lowered the risk of stroke or systemic embolism but increased the risk of major bleeding in patients with subclinical atrial fibrillation,
Testing for the possibility of a drug-drug interaction (DDI) in patients undergoing percutaneous coronary intervention (PCI), investigators found that “concomitant administration of prasugrel with cangrelor
An understudied group that is at risk for venous thromboembolism (VTE), patients aged 90 years or older had outcomes with anticoagulation different from those in
In a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases—EXtended Antiplatelet Monotherapy) trial, clopidogrel had consistently better outcomes
The incidence of a primary outcome of a composite of cardiovascular death, stroke, or systemic embolism was not reduced by anticoagulation with edoxaban in patients
Aspirin is underused for secondary prevention of cardiovascular disease (CVD), particularly in low-income countries, according to a study of 51 countries with varying per-capita income
In persons with atrial fibrillation who have had an acute ischemic stroke, early use of direct oral anticoagulants (DOACs) lowered by 0.5 to 2.8 percentage
Older adults taking low-dose aspirin may need periodic measurements of hemoglobin concentrations, conclude authors who conducted a post hoc analysis of the ASPREE (ASPirin in
In patients with cancer and venous thromboembolism (VTE) events, prophylaxis of recurrence with direct oral anticoagulants (DOACs) was noninferior to low-molecular-weight heparins (LMWHs), a study shows.
Intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin in heterogeneous groups of patients in China with stroke of